Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma.
Two novel IL2-dependent cell lines, DERL-2 and DERL-7, were established from a patient with hepatosplenic gammadelta T cell lymphoma. This patient presented, at diagnosis, two discrete populations of CD56+ cells, one TCRgammadelta+, the second lacking T cell-restricted antigens. The cell lines derived displayed features corresponding to the two cellular components of the disease: DERL-2 was CD56+/CD3+/TcRgammadelta+ while DERL-7 was CD56+/CD3-/TcRgammadelta-. Along with CD56, the two cell lines shared the expression of CD7, CD2, CD158b and CD117. Karyotype analysis showed that both cell lines were near-diploid, with iso-7q and loss of one chromosome 10. In addition, DERL-2 showed 5q+ in all metaphases analyzed, while DERL-7 revealed loss of one chromosome 4. Genotypically, both cell lines shared the same STR pattern at nine loci and demonstrated an identical rearranged pattern of the T cell receptor genes beta, gamma and delta, with respect to the original tumor cells. These data indicated that both cell lines and the original neoplastic populations were T cell-derived and arose from a common ancestor. Among a large panel of cytokines tested, only SCF was able to substitute IL2 in supporting cell proliferation. Moreover, SCF and IL2 acted synergistically, dramatically enhancing cell growth. These cell lines may represent a model to further analyze the overlap area between T and NK cell malignancies, and may provide new information about the synergistic action of IL2 and SCF on normal and neoplastic T/NK cells.
Di Noto
R
R
CEINGE-Biotecnologie Avanzate and Dipartimento di Biochimica e Biotecnologie Mediche, Università Federico II, Naples, Italy.
Pane
F
F
Camera
A
A
Luciano
L
L
Barone
M
M
Lo Pardo
C
C
Boccuni
P
P
Intrieri
M
M
Izzo
B
B
Villa
M R
MR
Macrí
M
M
Rotoli
B
B
Sacchetti
L
L
Salvatore
F
F
Del Vecchio
L
L
D000328:Adult; D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D020732:Cytogenetic Analysis; D004357:Drug Synergism; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / Q000235:genetics; D005838:Genotype; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology* / Q000473:pathology*; D008297:Male; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis / Q000235:genetics; D019089:Stem Cell Factor / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000166:cytology*
D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2; D016692:Receptors, Antigen, T-Cell, gamma-delta; D019089:Stem Cell Factor